Skip to main content Accessibility help
  • Print publication year: 2015
  • Online publication date: November 2015

11 - Management of cancer of the head and neck

Related content

Powered by UNSILO
Adelstein, D. J., Koyfman, S. A., El-Naggar, A.K., et al. (2012). Biology and management of salivary gland cancers. Semin. Radiat. Oncol. 22, 245–253.
AJCC. (2009). AJCC Cancer Staging Manual, ed. Edge, S. B., Byrd, D. R., Compton, C. C., et al., 7th edn. Chicago: American Joint Committee on Cancer.
Al-Sarraf, M., LeBlanc, M., Giri, P. G., et al. (1998). Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomised intergroup study 0099. J. Clin. Oncol. 16, 1310–1317.
Ang, K. K., Trotti, A., Brown, B. W., et al. (2001). Randomised trial addressing risk features and time factors of surgery plus radiotherapy in advanced head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys., 51, 571–578.
Ang, K. K., Harris, J., Wheeler, R., et al. (2010). Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363, 24–35.
Ang, K. K., Zhang, Q., Rosenthal, D. I., et al. (2014). Randomised phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III or IV head and neck carcinoma: RTOG 0522. J. Clin. Oncol., JCO.2013.53.5633, published online on 25 August 2014.
Argiris, A., Li, Y., Forastiere, A., et al. (2004). Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of head and neck. Cancer 101, 2222–2229.
Armstrong, J. G., Harrison, L. B., Thaler, H. T., et al. (1992). The indications for elective treatment of the neck in cancer of the major salivary glands. Cancer 69, 615–619.
Baujat, B., Audry, H., Bourhis, J., et al. (2006). Chemotherapy as an adjunct to radiotherapy in locally advanced nasopharyngeal carcinoma. Cochrane Database Syst. Rev. Issue 4 Art No. CD004329.
Bernier, J., Domenge, C., Ozsahin, M., et al. (2004). Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 350, 1945–1952.
Blanchard, P., Bourhis, J., Lacas, B., et al. (2013). Taxane–cisplatin–fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis. J. Clin. Oncol. 31, 2854–2860.
Bonner, J. A., Harari, P. M., Giralt, J., et al. (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567–578.
Bourhis, J., Overgaard, J., Audry, H., et al. (2006). Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet, 368, 843–854.
British Association of Otorhinolaryngology. (2011). Head and Neck Cancers: Multidisciplinary Management Guidelines, 4th edn. London: ENT UK.
Cancer Research UK. (2010). UK Cancer Incidence (2010) by Country Summary, April 2013. (accessed December 2014).
Cooper, J. S., Pajak, T. F., Forastiere, A. A., et al. (2004). Postoperative concurrent radiotherapy and chemotherapy for high risk squamous cell carcinoma of the head and neck. N. Engl. J. Med. 350, 1937–1944.
Dulguerov, P., Jacobsen, M. S., Allal, A. S., et al. (2001). Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review. Cancer 92, 3012–3029.
Forastiere, A. A., Metch, B., Schuller, D. E., et al. (1992). Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J. Clin. Onco., 10, 1245–1251.
Forastiere, A. A., Goepfert, H., Maor, M., et al. (2003). Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N. Engl. J. Med. 349, 2091–2098.
Frank, S. J., Rosenthal, D. I., Petsuksiri, J., et al. (2010). Intensity modulated radiotherapy for cervical node squamous cell carcinoma metastasis from unknown head and neck primary site: M.D. Anderson Cancer Centre outcomes and patterns of failure. Int. J. Radiat. Oncol. Biol. Phys. 78, 1005–1010.
Ghi, M. G., Paccagnella, A., Ferrari, D., et al. (2014). Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction docetaxel/cisplatin/5-fluorouracil followed by CRT or CET/RT in patients with locally advanced squamous cell carcinoma of head and neck – A randomised phase III factorial study. J. Clin. Oncol. 32, 5s, suppl; abstr. 6004.
Gibson, M. K., Li, Y., Murphy, B., et al. (2005). Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 23, 3562–3567.
Grégoire, V., Ang, K. K., Budach, W., et al. (2014). Delineation of the neck node levels for head and neck tumours: A 2013 update, Consensus guidelines. Radiother. Oncol. 110, 172–181.
Jegoux, F., Metreau, A., Louvel, G., et al. (2013). Paranasal sinus cancer. Eur. Ann. Otorhinolaryngol. Head Neck Dis. 130, 327–335.
Langendijk, J. A., Leemans, C. R., Buter, J., et al. (2004). The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: A meta-analysis of the published literature. J. Clin. Oncol. 22, 4604–4612.
Langendijk, J. A., Doornaert, P., Verdonck-de Leeuw, I. M., et al. (2008). Impact of late treatment related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy.J. Clin. Oncol. 26, 3770–3776.
Lavaf, A., Genden, E. M., Cesaretti, J. A., et al. (2008). Adjuvant radiotherapy improves overall survival for patients with lymph node positive head and neck squamous cell carcinoma. Cancer 112, 535–543.
Lee, N., Harris, J., Garden, A. S., et al. (2009). Intensity-Modulated Radiation Therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation Therapy Oncology Group Phase II Trial 0225. J. Clin. Oncol. 22, 3684–3690.
Lee, A., Lin, J. C. and Ng, W. T. (2012). Current management of nasopharyngeal cancer. Semin. Radiat. Oncol. 22, 233–244.
Machtay, M., Moughan, J., Trotti, A., et al. (2008). Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer; An RTOG Analysis. J. Clin. Oncol. 26, 3582–3589.
Mehanna, H., Rattay, T., Smith, J., et al. (2009). Treatment and follow up of oral dysplasia – a systematic review and meta-analysis. Head Neck 31, 1600–1609.
Mehanna, H., Beech, T., Nicholson, T., et al. (2013). Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer – Systematic review and meta-analysis of trends by time and region. Head Neck 35, 747–755.
Mehanna, H. M., Wong, W. L., McConkey, C. C., et al. (2015). PET-NECK: a multi-centre, radomized, phase III, controlled trial (RCT) comparing PETCT guided active surveillance with planned neck dissection (ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients with head and neck squamous cell cancer (HNSCC) treated with primary radical chemoradiotherapy (CRT).J. Clin. Oncol., 33, 2015 (suppl; abstr 6009).
Mishra, R. C., Singh, D.N., Mishra, T. K., et al. (1996). Post-operative radiotherapy in carcinoma buccal mucosa, a prospective randomised trial. Eur. J. Surg. Oncol. 22, 502–504.
Moore, E. J. and Hinni, M. L. (2013). Critical review: Transoral laser microsurgery and robotic assisted surgery for oropharynx cancer including human papillomavirus-related cancer. Int. J. Radiat. Oncol. Biol. Phys. 85, 1163–1167.
National Cancer Intelligence Network. (2010). Profile of Head and Neck Cancers in England – Incidence, Mortality and Survival.Oxford: Oxford Cancer Intelligence Unit.
Nutting, C. M., Morden, J. P., Harrington, K. J., et al. (2011). Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): A phase 3 multicentre randomised controlled trial. Lancet Oncol. 12, 127–136.
Overgaard, J., Hansen, H., Specht, L., et al. (2003). Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362, 933–940.
Parsons, J. T., Medenhall, W. M., Stringer, S. P., et al. (2002). Squamous cell carcinoma of the oropharynx: surgery, radiation therapy or both. Cancer 94, 2967–2980.
Pignon, J. P., le Maître, A., Maillard, E., et al. (2009). Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother. Oncol. 92, 4–14.
Pointreau, Y., Garaud, P., Chapet, S., et al. (2009). Randomised trial of induction chemotherapy with cisplatin and 5FU with or without docetaxel for larynx preservation. J. Natl. Cancer Inst. 101, 498–506.
Pow, E. H., Kwong, D. L., McMillan, A. S., et al. (2006). Xerostomia and quality of life after intensity-modulated radiotherapy vs conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial results on a randomised controlled trial. Int. J. Radiat. Oncol. Biol. Phys. 66, 981–991.
Shanmugaratnam, K., Sobin, L. H. and World Health Organization. (1978). Histological Typing of Upper Respiratory Tract Tumours. International Histological Classification of Tumours: no. 19.Geneva: World Health Organization.
Sher, D. J., Balboni, T. A., Haddad, R. I., et al. (2011). Efficacy and toxicity of chemoradiotherapy using intensity modulated radiotherapy for unknown primary of head and neck. Int. J. Radiat. Oncol. Biol. Phys. 80, 1405–1411.
Takes, R. P., Strojan, P., Silver, C. E., et al. (2012). Current trends in initial management of hypopharyngeal cancer: the declining use of open surgery. Head Neck 34, 270–281.
Tandon, S., Shahab, S., Benton, J. I., et al. (2008). Fine needle aspiration cytology in a regional head and neck cancer center: comparison with a systematic review and meta-analysis. Head Neck 30, 1246–1252.
Vermorken, J. B., Mesia, R., Rivera, F., et al. (2008). Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359, 1116–1127.
Vermorken, J. B., Stöhlmacher-Williams, J., Davidenko, I., et al. (2013). Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 14, 697–710.
Weller, M. D., Nankivell, P.C., McConkey, C., et al. (2010). The risk and interval to malignancy of patients with laryngeal dysplasia; A systematic review of case series and meta-analysis. Clin. Otolaryngol. 35, 364–372.